Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cardiol Therapeutics Inc T.CRDL.W.A


Primary Symbol: T.CRDL Alternate Symbol(s):  CRDL

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.


TSX:CRDL - Post by User

Post by Youhillmanon Apr 22, 2021 8:36am
103 Views
Post# 33043308

CRDL - COVID & Healthcare Conference at 4:15 today

CRDL - COVID & Healthcare Conference at 4:15 today

Elsley is participating in a panel discussion with 5 other companies to discuss COVID, it will be great to hear more about their FDA 2 & 3 trials.

Here's the link to register along with an outline of the conference...

https://us02web.zoom.us/webinar/register/WN_EvaJqLnXSMaARxMZtciq-g

COVID & Healthcare Conference Reunion - A Year in Review

Description
Almost one year ago we hosted our first virtual conference, COVID & Healthcare, where we showcased several small cap Canadian healthcare companies that responded quickly to the newly emerging pandemic and were already developing COVID related products, treatments, and therapies. We have followed their progress over the past year and thought it was fitting to invite a few back for an update, a Q&A and maybe even a virtual cocktail or two. 

Join Adelaide Capital on April 22nd at 4:15pm ET for a throwback BYOB to hear how these Canadian companies have helped shape the global response to the pandemic over the past year. We are also thrilled that Eden Rahim, Portfolio Manager of Next Edge Capital agreed to return once again to give an overview on investing in healthcare during these tumultuous times. 

We are hosting this event in support of Team Tina Byers’ fundraiser for the Leukemia & Lymphoma Society of Canada. One of the themes we have seen over the course of the pandemic is the lack of funding, research, diagnosis, and treatment for other life-threatening illnesses. Leukemia & Lymphoma is one close to our hearts, so we ask that anyone that is able to make a donation considering doing it in support of Team Tina Byers here: https://bit.ly/3r93cut . 

Presenting Companies: Appili Therapeutics (APLI), Cardiol Therapeutics (CRDL), iFabric Corp (IFA), Lexagene Holdings (LXG), Microbix Biosciences (MBX), SQI Diagnostics (SQI)

Keynote: Eden Rahim, Portfolio Manager, Next Edge Capital

Apr 22, 2021 04:15 PM in Eastern Time (US and Canada)


<< Previous
Bullboard Posts
Next >>